Datopotamab Deruxtecan, often abbreviated as DATO, represents the significant advancement regarding targeted cancer treatment. This novel antibody-drug conjugate combines an monoclonal antibody specifically focused on https://lawsonfcnt964974.pointblog.net/datopotamab-deruxtecan-the-promising-antibody-drug-compound-92097694